newsfilter
← Latest News
Business Wire·

Furiex Pharmaceuticals Announces Acceptance to Late-Breaking Abstract Session at Digestive Disease Week 2014

MORRISVILLE, N.C.--(BUSINESS WIRE)--Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) today announced that results from its two Phase III clinical trials of eluxadoline in patients with diarrhea-predominant irritable bowel syndrome will be presented in a Late-Breaking Abstract Session at Digestive Disease Week (DDW) 2014, to be held May 3-6 at McCormick Place in Chicago, IL.